Pharma firm Everest Organics said today that the US health regulator inspected its Aroor plant and has made one observation.
"The United States Food and Drug Administration (USFDA) inspected our facility at village Aroor from February 27, 2017 to March 3, 2017. There is only one observation," Everest Organics said in a filing to BSE.
The company believes that this is of minor nature and corrective and preventive action for this observation will be presented to the regulator shortly, it added.
Everest Organics develops, manufactures and markets a broad range of APIs and bulks drugs intermediates. It exports the products to over 20 countries.
Shares of Everest Organics were today trading 4.84 per cent higher at Rs 72.60 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
